Sogroya® (Somapacitan): The First Once-Weekly Long-Acting Growth Hormone Therapy
Novo Nordisk announced that its innovative growth hormone analogue Sogroya® (somapacitan) has been approved by the US Food and Drug Administration (FDA) for the treatment of growth hormone deficiency (GHD) in adults and children.
As the world’s first once-weekly, long-acting recombinant human growth hormone (GH) therapy, Sogroya is expected to significantly improve patient adherence as an alternative to traditional daily injection regimens.
Key Information Highlights
Breakthrough Dosing Frequency:
Sogroya’s patented technology extends the half-life of the drug, reducing the frequency of treatment from once-daily to once-weekly, reducing the burden on patients.
Clinical studies show that over 80% of adult and pediatric patients prefer weekly dosing regimens (vs. daily injections).
Clinical efficacy validation:
Adult GHD (REAL 1 trial): Sogroya significantly improved insulin-like growth factor-1 (IGF-1) levels over 52 weeks with non-inferior efficacy to daily growth hormone (Genotropin®).
Paediatric GHD (REAL 4 trial): annualised growth rate (AHV) was comparable to the daily treatment group with a favourable safety profile.
Patient Convenience:
Pre-filled injection pen design supports home dosing and reduces healthcare resource use.
Safety And Accessibility
Common adverse reactions include injection site reactions, headache and arthralgia, and are generally similar to conventional growth hormone.
Novo Nordisk plans to enhance drug accessibility through patient assistance programmes (e.g., [name of programme]), with prices expected to be approximately 20% higher than daily therapies, but with potentially lower overall care costs.
Clinical Study Shows Effectiveness Of Sogroya® In Paediatric Patients
In a clinical study of growth hormone deficiency in children, a once-weekly injection regimen of Sogroya® somapacitan helped children reach their expected growth targets for annualised growth rate (AHV).
This result further supports the potential of Sogroya® in paediatric patients and offers new therapeutic hope for children with GHD worldwide.
In summary, Sogroya®, as an innovative long-acting growth hormone formulation, is gradually gaining acceptance and application worldwide.
Its once-weekly dosing regimen not only improves the convenience of treatment for patients, but also brings new therapeutic options for patients with growth hormone deficiency.
However, DengYue’s efforts to increase the affordability of the medicine are critical to ensuring that more patients benefit from it.
We welcome you to reach out to us to buy Somapacitan. DengYueMedicine is here to provide detailed medicine information, pricing, and support to ensure a smooth and reliable buying experience.
Feel free to contact us anytime to discuss your needs or ask any questions about the medicine.
Information from DengYueMed, China Drug Import and Export Wholesaler offers this information as a guide, not a substitute for professional medical advice. Consult your doctor before any treatment.
